Last reviewed · How we verify
PSB205
At a glance
| Generic name | PSB205 |
|---|---|
| Sponsor | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (PHASE3)
- A Study of QL1706 in Subjects With Advanced Malignant Tumor (PHASE1)
- A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors (PHASE1)
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) (PHASE1, PHASE2)
- A Study of PSB205 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PSB205 CI brief — competitive landscape report
- PSB205 updates RSS · CI watch RSS
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics) portfolio CI